PTC THERAPEUTICS, INC. for PTC THERAPEUTICS, INC.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 22, 2024 | $100,000 | Replaced |
| 2nd Quarter - Amendment | Jan 21, 2025 | $90,000 | Replaced |
| 2nd Quarter - Amendment | Feb 4, 2025 | $90,000 | Yes |
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
Awareness of Aromatic L-amino acid decarboxylase deficiency (AADCD) Improving diagnostic testing for rare pediatric genetic diseases Awareness of Huntingtons Disease Awareness of Friedreichs Ataxia Awareness of Phenylketonuria
| Lobbyist | Covered position, as disclosed |
|---|---|
| NICHOLAS BRAUGHTON | — |
| JONATHAN REA MCPHERSON | — |
| LEAH DUFFY SVOBODA | — |
Health Issues HCR
Issues related to access to rare disease therapies Issues related to FDA modernization and rare disease drug development Issues related to the Accelerated Approval Program Issues related to Public Law No. 117-169 -The Inflation Reduction Act of 2022 Issues related to rare disease diagnosis and testing Issues related to alternative funding programs Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R. 7384 - Creating Hope Reauthorization Act of 2024
| Lobbyist | Covered position, as disclosed |
|---|---|
| NICHOLAS BRAUGHTON | — |
| JONATHAN REA MCPHERSON | — |
| LEAH DUFFY SVOBODA | — |
Medicare/Medicaid MMM
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
| Lobbyist | Covered position, as disclosed |
|---|---|
| NICHOLAS BRAUGHTON | — |
| JONATHAN REA MCPHERSON | — |
| LEAH DUFFY SVOBODA | — |
Taxation/Internal Revenue Code TAX
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act and H.R. 7024 - The Tax Relief for American Families and Workers Act of 2024 Issues related to the Orphan Drug Tax Credit
| Lobbyist | Covered position, as disclosed |
|---|---|
| NICHOLAS BRAUGHTON | — |
| JONATHAN REA MCPHERSON | — |
| LEAH DUFFY SVOBODA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.